FDA grants traditional approval to Novartis’ Fabhalta for IgAN
RegulatoryapprovedFabhaltaPositive
AI Analysis
Summary
The FDA granted traditional approval to Novartis for Fabhalta to slow kidney function decline in adults with primary IgAN at risk of disease progression. This represents a significant regulatory milestone for the treatment of this rare kidney disease.
Outcome Details
FDA traditional approval granted
Importance:9/10
Sentiment:
0.90
FDA approvalNephrologyRare diseaseIgAN
Related Companies
Read the original article
Published by Pharmaceutical Technology on July 17, 2026 10:18 AM